Key takeaways
- • Frequency: Common — 8-15% report awareness.
- • Trial reference: Patient survey aggregation (8-15%).
- • Management: typically resolves within 4-8 weeks as the body adapts.
- • When to call doctor: see red-flag list below.
Why this happens
Weight loss reduces resting metabolic rate (RMR) by ~10-15% in many patients, leading to feeling colder. Some patients report hot flashes during initial titration — likely related to hormonal shifts during rapid weight loss. Thyroid function can also be unmasked when GLP-1 causes weight changes.
How to manage it
- Maintain protein + balanced caloric intake to preserve metabolic rate
- Layer clothing for cold intolerance
- Identify hot-flash triggers (caffeine, spicy food, alcohol)
- Check TSH at baseline + 6 months on GLP-1
- Address sleep disruption from temperature shifts
- Stay hydrated — fluid status affects thermoregulation
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Persistent low body temperature + fatigue (hypothyroidism workup)
- • Hot flashes + sleep disruption + mood changes (consider perimenopause overlap)
- • Sudden fever (separate from drug effect — infection screening)
- • Significant cold intolerance + hair loss + weight loss (thyroid evaluation)
Drug-specific notes
- All GLP-1s: Class effect from weight loss + metabolic adaptation; usually settles by month 6
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)